日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Long-Term Durability of Ciliary Neurotrophic Factor-Releasing Revakinagene Taroretcel-lwey in Individuals With Retinal Degenerative Disorders.

睫状神经营养因子释放剂Revakinagene Taroretcel-lwey在视网膜退行性疾病患者中的长期疗效

期刊:Investigative Ophthalmology & Visual Science
影响因子:4.7
doi:10.1167/iovs.66.11.3
Kauper Konrad, Nystuen Arne, Orecchio Lisa, Gonzalez-Lopez Eugene, Lee Alice, Duncan Jacque L, Stewart Jay M, Aaberg Thomas Jr
神经科学
发表日期：2025
文献求助 收藏

Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes

随机对照试验：玻璃体内注射阿柏西普治疗放射性视网膜病变——1年疗效

期刊:Investigative Ophthalmology & Visual Science
影响因子:4.7
doi:10.1167/iovs.64.7.35
Trejo Corona, Stephanie; Villanueva Boone, Cecilia; Ali, Amna M; Moore, Chelsey; Brown, Alexandra; Munoz, Jose; Aaberg, Thomas Jr; Schefler, Amy C
视网膜病变
神经科学
发表日期：2023
文献求助 收藏

Unilateral Multiple Extramedullary Plasmacytoma of the Choroid and Conjunctiva: A Case Report

单侧脉络膜和结膜多发性髓外浆细胞瘤：病例报告

期刊:Journal of VitreoRetinal Diseases
影响因子:0.8
doi:10.1177/2474126419893175
Mohamed, Shymaa; Silvasi, Truman; Kubat, Anthony; Aaberg, Thomas Jr
细胞生物学
骨髓瘤
发表日期：2020
文献求助 收藏

Visual acuity, oncologic, and toxicity outcomes with (103)Pd vs. (125)I plaque treatment for choroidal melanoma

脉络膜黑色素瘤采用(103)Pd与(125)I斑块治疗的视力、肿瘤学和毒性结果比较

期刊:Brachytherapy
影响因子:1.8
doi:10.1016/j.brachy.2017.01.012
Patel, Kirtesh R; Prabhu, Roshan S; Switchenko, Jeffrey M; Chowdhary, Mudit; Craven, Caroline; Mendoza, Pia; Danish, Hasan; Grossniklaus, Hans E; Aaberg, Thomas M Sr; Aaberg, Thomas Jr; Reddy, Sahitya; Butker, Elizabeth; Bergstrom, Chris; Crocker, Ian R
黑色素瘤
肿瘤
毒理研究
肿瘤免疫
发表日期：2017
文献求助 收藏